Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Nuvation Bio
Biotech
Nuvation halts BET inhibitor after considering phase 1 data
After taking a look at phase 1 data, Nuvation will halt work on its one-time lead BD2-selective BET inhibitor while considering the program’s future.
James Waldron
Aug 5, 2024 11:02am
John Cox gets new biotech CEO gig at Dyne—Chutes & Ladders
Mar 29, 2024 9:30am
Nuvation drops tumor asset and reduces staff by a third
Aug 1, 2022 9:35am
Roche taps new CEO—Chutes & Ladders
Jul 22, 2022 9:30am
Nuvation's new solid tumor focus hits snag on FDA hold
Jun 27, 2022 10:05am
Former AbbVie R&D chief tapped to run Tessera—Chutes & Ladders
Jun 3, 2022 9:30am
